More sweetness than light? A search for the causes of diabetic vasculopathy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Sphingosine-1-phosphate and modulation of vascular tone.Cardiovascular research · 2009
   Review
2. Indolent course of tubulointerstitial disease in a mouse model of subpressor, low-dose nitric oxide synthase inhibition.American journal of physiology. Renal physiology · 2008
   Article
3. Mannan binding lectin as an adjunct to risk assessment for myocardial infarction in individuals with enhanced risk.The Journal of experimental medicine · 2005
   Article

Corrections and comments

• Comment on
  Nitric oxide synthases: which, where, how, and why?1997
• Comment on
  Cellular and molecular mechanisms of endothelial cell dysfunction.1997
• Comment on
  Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site.2001

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as